| Prev Close | 40.76 |
| Open | 40.53 |
| Day Low/High | 40.43 / 40.71 |
| 52 Wk Low/High | 35.77 / 42.36 |
| Volume | 2.46M |
| Avg Volume | 3.57M |
GlaxoSmithKline Plc (GSK)
40.54
0.22
0.55
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.48B |
| Market Cap | 101.62B |
| EPS | 2.00 |
| P/E Ratio | 23.73 |
| Div & Yield | 2.06 (5.14%) |
Latest News
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Get Ready to Buy the Big Upside Breakout on GlaxoSmithKline
Let's check out the charts.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Novice Trade: EWU United Kingdom ETF
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Novice Trade: EWU ETF
This portfolio cannot be trusted to be diversified enough.
GlaxoSmithKline Gets a Boost
Drugmaker's charts show positive signs ahead.
Gilead's Earnings Fail to Impress
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Innoviva Is Attractive Play in Biotech
Strong balance sheet and royalties are big positives for Innoviva.
Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
GlaxoSmithKline Looks Poised for an Upside Move
GSK is still below the declining 200-day moving average line but a rally of $2 will challenge the line.
10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
5 Products You Didn't Know Were Made By Pfizer
Pfizer is reportedly planning to sell its consumer healthcare business in an auction next month
European Stocks Euphoria Is Running High ... Maybe Too High
European stock markets are priced almost to perfection ahead of an earnings deluge.
Nascar Champ Danica Patrick--'I'm Not That Into Cars'
You would think that Nascar champion Danica Patrick would be a gear head who can talk makes, models and car parts and and car collector with garages brimming with rare autos. You would be wrong.
Another Day - Another Busy Slate of Earnings
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
China Was Right to Walk Away From Failed U.S. Trade Talks
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
These Stocks Are Showing Red Flags -- Here's When to Sell
You don't want to own these four 'toxic stocks'.
GlaxoSmithKline Continues to Strengthen
Technical indicators suggest GSK can see further significant gains in 2017.
More Companies Pull Advertising to Protest Google's Treatment of Extremist Content
Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.
Still Bullish on GlaxoSmithKline
After another technical look at GSK, this FTSE component is still going strong.
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Why I'm Optimistic About GlaxoSmithKline
Check out GSK's well developed base pattern.
